Mutual Advisors LLC Acquires 8,856 Shares of Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jun 23rd, 2023

Mutual Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 6.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,752 shares of the biopharmaceutical company’s stock after acquiring an additional 8,856 shares during the quarter. Mutual Advisors LLC’s holdings in Pfizer were worth $5,865,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. RB Capital Management LLC lifted its position in shares of Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 341 shares during the period. Ironwood Wealth Management LLC. lifted its position in shares of Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after purchasing an additional 400 shares during the period. United Bank lifted its position in shares of Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares during the period. Ergoteles LLC lifted its position in shares of Pfizer by 136.3% in the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp lifted its position in shares of Pfizer by 6.4% in the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the period. 67.80% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Monday, May 8th. The stock was acquired at an average price of $38.58 per share, for a total transaction of $38,580.00. Following the completion of the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $231,480. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Pfizer Stock Performance

PFE opened at $38.73 on Friday. The company’s fifty day moving average price is $38.77 and its two-hundred day moving average price is $42.81. The company has a market cap of $218.64 billion, a price-to-earnings ratio of 7.62, a PEG ratio of 1.33 and a beta of 0.64. The company has a current ratio of 1.37, a quick ratio of 1.11 and a debt-to-equity ratio of 0.31. Pfizer Inc. has a 1-year low of $36.17 and a 1-year high of $54.93.

Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.00 by $0.23. The company had revenue of $18.28 billion during the quarter, compared to the consensus estimate of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The firm’s revenue for the quarter was down 28.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.62 earnings per share. On average, analysts expect that Pfizer Inc. will post 3.35 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 5th. Investors of record on Friday, July 28th will be issued a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 4.23%. Pfizer’s dividend payout ratio (DPR) is presently 32.28%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Morgan Stanley dropped their price target on shares of Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Monday, April 10th. Daiwa Capital Markets downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 target price on the stock. in a research report on Thursday, May 11th. Wells Fargo & Company dropped their target price on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Friday, March 17th. Jefferies Financial Group initiated coverage on shares of Pfizer in a research report on Monday, March 6th. They set a “hold” rating and a $43.00 target price on the stock. Finally, Bank of America dropped their target price on shares of Pfizer from $50.00 to $45.00 and set a “neutral” rating on the stock in a research report on Friday, April 21st. Nine equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $47.33.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.